DRREDDY - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.5
| Stock Code | DRREDDY | Market Cap | 1,06,107 Cr. | Current Price | 1,272 ₹ | High / Low | 1,376 ₹ |
| Stock P/E | 33.0 | Book Value | 376 ₹ | Dividend Yield | 0.63 % | ROCE | 12.7 % |
| ROE | 10.7 % | Face Value | 1.00 ₹ | DMA 50 | 1,282 ₹ | DMA 200 | 1,267 ₹ |
| Chg in FII Hold | -1.20 % | Chg in DII Hold | 0.28 % | PAT Qtr | -219 Cr. | PAT Prev Qtr | 90.6 Cr. |
| RSI | 45.3 | MACD | -6.39 | Volume | 13,47,161 | Avg Vol 1Wk | 9,03,574 |
| Low price | 1,148 ₹ | High price | 1,376 ₹ | PEG Ratio | 4.71 | Debt to equity | 0.18 |
| 52w Index | 54.1 % | Qtr Profit Var | -118 % | EPS | 38.6 ₹ | Industry PE | 32.5 |
Dr. Reddy’s Laboratories shows mixed fundamentals with a reasonable P/E ratio compared to industry average, but weak ROCE and ROE, and a sharp decline in quarterly profits. Technically, the stock is trading around its 50 DMA and 200 DMA, with RSI at 45.3 and MACD negative, indicating bearish to neutral momentum. While the company has strong market capitalization and low debt, recent losses and valuation concerns make it a cautious candidate for swing trading.
💡 Optimal Entry Price: Around 1,240–1,260 ₹ (near support levels close to DMA 200).
📈 Exit Strategy: If already holding, consider booking profits near 1,340–1,360 ₹ (short-term resistance) or exit if price falls below 1,220 ₹ (support zone).
✅ Positive
- 📈 Large market cap of 1,06,107 Cr. provides stability.
- 💰 Low debt-to-equity ratio of 0.18 ensures financial safety.
- 📊 EPS at 38.6 ₹ provides a solid earnings base.
- 📉 Price trading near DMA 50 and DMA 200, offering technical support.
⚠️ Limitation
- 📉 Weak ROCE at 12.7% and ROE at 10.7% indicate limited efficiency.
- 📉 Elevated PEG ratio at 4.71 suggests valuation concerns relative to growth.
- 📉 Dividend yield at 0.63% is modest.
📰 Company Negative News
- 📉 Decline in FII holding (-1.20%) shows reduced foreign investor confidence.
- 📉 PAT dropped sharply from 90.6 Cr. to -219 Cr. in the latest quarter.
- 📉 Quarterly profit variation (-118%) highlights earnings volatility.
🌟 Company Positive News
- 📈 Increase in DII holding (+0.28%) signals domestic institutional support.
- 📊 Strong 52-week index performance (+54.1%) shows price resilience despite weak fundamentals.
🏭 Industry
- 📊 Industry P/E at 32.5, close to Dr. Reddy’s 33.0, suggesting sector is fairly valued.
- 📈 Pharmaceuticals industry remains resilient with long-term demand growth, though margins are under pressure.
📌 Conclusion
Dr. Reddy’s Laboratories presents a cautious swing trade opportunity. While market cap, low debt, and sector resilience are positives, weak efficiency metrics, declining profits, and bearish technicals limit upside. Entry is favorable near 1,240–1,260 ₹, with profit booking advised around 1,340–1,360 ₹. Risk management is crucial due to earnings volatility and valuation concerns.